Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamtidine SCHEMBL29398554 | 1.00 | HRH2 (0.61) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 | |
| SCHEMBL11296591 | 1.00 | HRH2 (0.61) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 | |
| SCHEMBL11093446 | 0.96 | HRH2 (0.56) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 | |
| SCHEMBL11098343 | 0.96 | HRH2 (0.56) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 | |
| SCHEMBL10750433 | 0.89 | HRH2 (0.56) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 | |
| SCHEMBL11011262 | 0.88 | SMN1; SMN2 (0.57) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 | |
| Roxatidine Acetate SCHEMBL9545521 | 0.88 | HRH2 (0.74) | HRH2HRH3 | |
| SCHEMBL11100561 | 0.88 | HRH3 (0.55) | TSHRHRH3 | |
| SCHEMBL10750980 | 0.88 | SMN1; SMN2 (0.54) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 | |
| Lavoltidine SCHEMBL1142 | 0.87 | SMN1; SMN2 (0.55) | HRH2SMN1; SMN2TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | claimed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | claimed |
| WO-2015169957-A1 | PHARMACEUTICAL COMBINATIONS OF RIVAROXABAN AND H2-RECEPTOR ANTAGONISTS | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-11-12 | — | — | WO | claimed |
| EP-2942058-A1 | Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-11-11 | — | — | EP | claimed |
| WO-2015155297-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND H2-RECEPTOR ANTAGONISTS | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-10-15 | — | — | WO | claimed |
| EP-2929884-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND H2-RECEPTOR ANTAGONISTS | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-10-14 | — | — | EP | claimed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| WO-1997047292-A1 | USE OF H2-ANTAGONISTS FOR THE MANUFACTURE OF A TOPICAL COMPOSITION FOR THE TREATMENT OF COLDS | THE PROCTER & GAMBLE COMPANY (US) | 1997-12-18 | — | — | WO | claimed |
| US-5538737-A | WATER-IN-OIL EMULSION IN CAPSULE FORM | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1996-07-23 | — | — | US | claimed |
| WO-1996016640-A1 | ORAL COMPOSITIONS OF H2-ANTAGONISTS | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1996-06-06 | — | — | WO | claimed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | claimed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| EP-0138464-B1 | 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1989-11-15 | — | — | EP | claimed |
| US-4673677-A | 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE | PFIZER INC. (US) | 1987-06-16 | — | — | US | claimed |
| US-4554276-A | ENZYME INHIBITORS, ANTIULCER AGENTS | PFIZER INC. (US) | 1985-11-19 | — | — | US | claimed |
| EP-0138464-A2 | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives | PFIZER INC. (US) | 1985-04-24 | — | — | EP | claimed |